Answers are grounded in this paper and cite their sources.
Comprehensive review highlights SGLT2 inhibitors' roles in nephrolithiasis prevention, suggesting novel pathways for metabolic disease management.
Nephrolithiasis (NL) is frequently associated with metabolic disorders such as type 2 diabetes mellitus (T2DM),obesity, and chronic kidney disease (CKD), all of which alter urinary composition and increase the risk of calciumoxalate and uric acid stone formation. Sodium-glucose cotransporter-2 inhibitors (SGLT2i), originally developedfor glycemic control in T2DM, have emerged as promising agents with both renoprotective and anti-lithogeniceffects. These effects are mediated through mechanisms such as osmotic diuresis, increased urinary citrate excretion (citraturia), and modulation of urinary pH, all contributing to reduced supersaturation and stone risk. Thisreview provides a comprehensive overview of the mechanisms by which SGLT2i may prevent stone formation,alongside a critical analysis of the current clinical evidence.
No takes yet. Share an insight, caveat, or question.
Lombardi et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: